fulvestrant sold brand name faslodex among others antiestrogenic medication used treat hormone receptor hrpositive metastatic breast cancer postmenopausal women disease progression well hrpositive advanced breast cancer combination abemaciclib palbociclib women disease progression endocrine given injection fulvestrant selective estrogen receptor degrader serd firstinclass works binding estrogen receptor destabilizing causing cells normal protein degradation processes destroy fulvestrant approved medical use united states fulvestrant used treatment hormone receptor positive metastatic breast cancer locally advanced unresectable disease postmenopausal women given cochrane review found safe effective first line second line endocrine also used treat erpositive advanced metastatic breast cancer combination abemaciclib palbociclib women disease progression firstline endocrine due medications chemical structure similar estrogen interact immunoassays blood estradiol concentrations show falsely elevated improperly lead discontinuing fulvestrant used treatment peripheral precocious puberty girls fulvestrant provided castor oil solution also containing alcohol benzyl alcohol benzyl supplied concentration fulvestrant used women kidney failure common occurring people adverse effects include nausea injection site reactions weakness elevated transaminases common adverse effects include urinary tract infections hypersensitivity reactions loss appetite headache blood clots veins hot flushes vomiting diarrhea elevated bilirubin rashes back large clinical trial incidence venous thromboembolism vte fulvestrant fulvestrant antiestrogen acts antagonist estrogen receptor er additionally selective estrogen receptor degrader works binding estrogen receptor making hydrophobic makes receptor unstable misfold turn leads normal processes inside cell degrade addition antiestrogenic activity fulvestrant agonist g proteincoupled estrogen receptor gper albeit relatively low affinity nm relative nm fulvestrant intramuscular injection slowly absorbed maximal levels cmax reached days average range elimination halflife fulvestrant intramuscular injection times longer halflife fulvestrant intravenous injection indicating long halflife intramuscular injection due slow absorption injection levels fulvestrant mgmonth intramuscular injection single additional mg loading dose day therapy postmenopausal women advanced breast cancer ngml pgml peak ngml pgml trough single dose ngml pgml peak ngml pgml trough multiple doses steady fulvestrant cross barrier animals may humans accordingly effects fulvestrant brain function observed preclinical clinical fulvestrant highly bound plasma bound low density lipoprotein low density lipoprotein high density lipoprotein sex hormonebinding fulvestrant appears metabolized along similar pathways endogenous steroids may involved noncytochrome routes appear important inhibit cytochrome enzymes elimination almost via fulvestrant form colloidal aggregates certain concentration ranges limit activity well produce bellshaped fulvestrant also known synthetic estrane steroid derivative estradiol alkylsulfinyl moiety added endogenous estrogen receptor discovered rational drug design selected development via phenotypic fulvestrant first selective estrogen receptor degrader approved united states europe uk national institute health clinical excellence nice said found evidence faslodex significantly better existing treatments widespread use would good use resources countrys national health service first months treatment faslodex starts loading dose costs subsequent treatments cost monthcitation needed months ending june uk price excluding vat months supply anastrozole arimidex patent cost penceday letrozole femara cost original patent faslodex expired october drugs subject premarketing regulatory review eligible patent extension reason astrazeneca got extension patent december astrazeneca filed later patents generic version faslodex approved fda however mean product necessarily commercially available possibly drug patents andor drug later patent faslodex expires january atossa genetics patent administration fulvestrant breast via microcatheter invented susan fulvestrant studied endometrial cancer results promising development use fulvestrant given orally efforts made develop serd drugs taken mouth including brilanestrant clinical success fulvestrant also led efforts discover develop parallel drug class selective androgen receptor degraders acid oral prodrug fulvestrant httpsenwikipediaorgwikifulvestrant